Vepdegestrant (ARV-471) Archives - Arvinas

09DecDecember 9, 2025

Circulating Tumor DNA Biomarker Analyses of a Phase 1/2 Study Evaluating Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in ER+/HER2- Advanced Breast Cancer

09DecDecember 9, 2025

Real-world Prevalence of ESR1 Mutations Among Patients With ER+/HER2- Metastatic Breast Cancer After First-line Treatment With Endocrine Therapy and/or a CDK4/6 Inhibitor

09DecDecember 9, 2025

Subgroup Analyses of VERITAC-2: A Phase 3 Trial of Vepdegestrant, a PROTAC ER Degrader, vs Fulvestrant in ER+/HER2- Advanced Breast Cancer

09NovNovember 9, 2025

Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast Cancer

09NovNovember 9, 2025

Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data

22OctOctober 22, 2025

Vepdegestrant, a PROTAC ER Degrader, Induces Greater ER Degradation and Antitumor Activity Relative to SERDs in Preclinical ER+ Breast Cancer Models

17OctOctober 17, 2025

TACTIVE-N: Phase 2 Study of Neoadjuvant Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal ER+/Human Epidermal Growth Factor Receptor 2-Negative Localized Breast Cancer

17OctOctober 17, 2025

Patient-Reported Outcomes (PROs) with Vepdegestrant (VEP) vs Fulvestrant (FUL) in Patients (pts) with Estrogen Receptor (ER) 1 Gene Mutated (ESR1m) ER+/Human Epidermal Growth Factor Receptor 2 (HER2): Advanced Breast Cancer (aBC) in the Phase 3 VERITAC-2 Trial

21SepSeptember 21, 2025

Absorption, Metabolism, Excretion, and Pharmacokinetics of [¹⁴C] Vepdegestrant in Healthy Adult Participants

14SepSeptember 14, 2025

A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants